HC Wainwright Estimates Inventiva FY2026 Earnings

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) – Equities research analysts at HC Wainwright issued their FY2026 earnings estimates for Inventiva in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst A. Ghosh expects that the company will post earnings of ($0.59) per share for the year. HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Inventiva’s current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Inventiva’s FY2027 earnings at ($0.58) EPS, FY2028 earnings at ($0.50) EPS, FY2029 earnings at ($0.46) EPS and FY2030 earnings at ($0.09) EPS.

A number of other brokerages also recently issued reports on IVA. Piper Sandler reissued an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Truist Financial upped their price objective on Inventiva from $13.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, October 2nd. Wall Street Zen raised Inventiva from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. Guggenheim increased their price objective on Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Finally, Cantor Fitzgerald assumed coverage on Inventiva in a report on Friday, July 17th. They issued an “overweight” rating for the company. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $14.67.

Inventiva Stock Up 1.1%

Shares of IVA opened at $3.84 on Monday. The stock’s 50 day moving average is $3.71 and its two-hundred day moving average is $4.82. Inventiva has a twelve month low of $2.82 and a twelve month high of $7.29.

Inventiva (NASDAQ:IVA) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The company had revenue of $0.75 million for the quarter.

Institutional Investors Weigh In On Inventiva

A number of institutional investors and hedge funds have recently modified their holdings of the company. Aberdeen Group plc raised its holdings in Inventiva by 36.3% during the third quarter. Aberdeen Group plc now owns 3,145,711 shares of the company’s stock worth $11,608,000 after purchasing an additional 837,938 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in Inventiva in the first quarter valued at $1,111,000. Commonwealth Equity Services LLC grew its holdings in Inventiva by 7.0% in the third quarter. Commonwealth Equity Services LLC now owns 89,853 shares of the company’s stock valued at $332,000 after purchasing an additional 5,857 shares during the last quarter. Engineers Gate Manager LP grew its holdings in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after purchasing an additional 43,280 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Inventiva by 78.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company’s stock valued at $142,000 after buying an additional 17,000 shares in the last quarter. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.